New HIV Drugs at CROI 2025

Conference Reports for NATAP

Conference on Retroviruses
and Opportunistic Infections
San Francisco, CA
March 9-12 2025


New HIV Drugs at CROI 2025

	Switch to DOR/ISL (100/0.25 mg) QD from Oral ART: an Open-Label Phase 3 Study in Adults with HIV-1 - (03/13/25) Switch to DOR/ISL (100/0.25 mg) QD from BIC/FTC/TAF: a Blinded Phase 3 Study in Adults with HIV-1 - (03/13/25) • Modeling Accurately Predicts Efficacious Islatravir QW Dose with no Lymphocyte and CD4 Changes - (03/11/25) • Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study published - (03/12/25) • Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir - (03/14/25) • VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - (03/13/25) • Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir - (03/13/25) • Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1 - (03/12/25) • Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor - (03/12/25) • Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor - (03/12/25) • MK-8527 PK/PD Threshold and Phase 2 Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis - (03/11/25) • In Vitro Resistance Profile for GS-1720, a Potent Once-Weekly Oral INSTI in Clinical Development - (03/11/25) • Pharmacokinetic Modeling of Missed Dose Scenario of Oral Weekly Islatravir Plus Lenacapavir - (03/11/25) • Bictegravir + Lenacapavir: Baseline and Week 48 Resistance Analyses in ARTISTRY-1 Phase 2 - (03/11/25) • Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks - (03/11/25) • A 24-Week Phase II Maintenance Study of TMB-365/TMB-380 Q8W in People With Suppressed HIV-1 Infection - (04/02/25) • A Multicenter Study of Albuvirtide Combined With 3BNC117 in Multidrug-Resistant HIV-1 Infection - (04/02/25)